MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Update

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,304,530 shares, an increase of 26.9% from the March 15th total of 1,816,131 shares. Based on an average trading volume of 801,291 shares, the days-to-cover ratio is presently 2.9 days. Currently, 5.6% of the company’s stock are sold short.

Institutional Trading of MAIA Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of MAIA. Jane Street Group LLC bought a new stake in MAIA Biotechnology in the fourth quarter valued at about $120,000. Geode Capital Management LLC grew its holdings in shares of MAIA Biotechnology by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after purchasing an additional 25,684 shares during the last quarter. Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology during the fourth quarter valued at approximately $35,000. Marshall Wace LLP bought a new position in shares of MAIA Biotechnology during the second quarter valued at approximately $29,000. Finally, Centric Wealth Management grew its holdings in shares of MAIA Biotechnology by 2.0% during the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after purchasing an additional 11,500 shares during the last quarter. 5.65% of the stock is owned by institutional investors.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN MAIA traded down $0.08 during midday trading on Thursday, reaching $1.35. 667,591 shares of the company’s stock were exchanged, compared to its average volume of 1,015,781. MAIA Biotechnology has a 52-week low of $0.87 and a 52-week high of $3.19. The stock has a market capitalization of $81.60 million, a PE ratio of -1.95 and a beta of 0.30. The business’s fifty day moving average price is $1.65 and its two-hundred day moving average price is $1.55.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its earnings results on Monday, March 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. Analysts predict that MAIA Biotechnology will post -1.3 earnings per share for the current fiscal year.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.